[{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"ab61b8a8-7577-42c8-aace-25d2ec073ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700721","created_at":"2023-01-26T15:02:55.768Z","updated_at":"2025-02-25T14:09:25.231Z","phase":"Phase 2","brief_title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","source_id_and_acronym":"NCT05700721","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 08/07/2025","primary_completion_date":" 08/07/2025","study_txt":" Completion: 08/07/2027","study_completion_date":" 08/07/2027","last_update_posted":"2025-02-17"},{"id":"527306d6-34b9-4ad0-b5f6-cf22600b56c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03968406","created_at":"2024-02-22T16:25:39.444Z","updated_at":"2025-02-25T15:11:11.864Z","phase":"Phase 1","brief_title":"Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers","source_id_and_acronym":"NCT03968406","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"ae36f3a0-eb85-44ba-afee-09efb5463d1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01434316","created_at":"2021-01-18T05:55:48.375Z","updated_at":"2025-02-25T16:51:08.574Z","phase":"Phase 1","brief_title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01434316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • RAD51","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • dinaciclib (MK-7965)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/11/2011","start_date":" 11/11/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-04"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"ffde309b-8c51-4b41-b83c-bcf6504849f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06606990","created_at":"2025-02-25T20:15:32.283Z","updated_at":"2025-02-25T20:15:32.283Z","phase":"Phase 1","brief_title":"Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers","source_id_and_acronym":"NCT06606990","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidnarulex (CX-5461)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/09/2025","start_date":" 09/09/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-16"},{"id":"2b33007a-0dee-4baa-8c83-5d27c6932cf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05659914","created_at":"2023-12-28T15:17:11.723Z","updated_at":"2025-02-25T15:00:45.040Z","phase":"Phase 2","brief_title":"Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations","source_id_and_acronym":"NCT05659914","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" HRD • RAD51","pipe":" | ","alterations":" HRD","tags":["HRD • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-10-18"},{"id":"5b18e518-5abe-49ce-9ea4-7ddcd3927bd8","acronym":"SPORE","url":"https://clinicaltrials.gov/study/NCT04666740","created_at":"2021-01-19T20:43:48.854Z","updated_at":"2025-02-25T16:10:54.810Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","source_id_and_acronym":"NCT04666740 - SPORE","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-10-14"},{"id":"9938550f-8e02-48a0-9be9-a575ea84f10a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02677038","created_at":"2021-01-18T13:03:11.604Z","updated_at":"2025-02-25T14:57:29.913Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Stage IV Pancreatic Cancer","source_id_and_acronym":"NCT02677038","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • ATM • HRD • BRCA • RAD51","pipe":" | ","alterations":" HRD • ATM mutation • BRCA mutation","tags":["BRCA1 • ATM • HRD • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2024-10-01"},{"id":"1d394ddd-86a9-4b8f-a2a2-adf734a97239","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502733","created_at":"2023-12-06T17:15:36.704Z","updated_at":"2024-07-02T16:34:25.709Z","phase":"Phase 1","brief_title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","source_id_and_acronym":"NCT03502733","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"aecf3ac5-9504-4f3a-9a5f-7cc5aaedb65d","acronym":"NCI-2019-03212","url":"https://clinicaltrials.gov/study/NCT03965689","created_at":"2021-01-18T19:30:37.082Z","updated_at":"2024-07-02T16:35:02.796Z","phase":"Phase 2","brief_title":"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy","source_id_and_acronym":"NCT03965689 - NCI-2019-03212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression","tags":["BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2024-05-17"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"f269309d-3a63-4270-8476-61faefe6970a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691517","created_at":"2023-01-20T16:00:14.301Z","updated_at":"2024-07-02T16:35:03.683Z","phase":"Phase 1","brief_title":"Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers","source_id_and_acronym":"NCT05691517","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alphalex-exatecan (CBX-12)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/13/2025","start_date":" 01/13/2025","primary_txt":" Primary completion: 10/15/2026","primary_completion_date":" 10/15/2026","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-05-14"},{"id":"3996d836-38db-4e27-8cc0-e1b7578a424b","acronym":"REPAIR","url":"https://clinicaltrials.gov/study/NCT03044795","created_at":"2021-01-18T14:59:46.036Z","updated_at":"2024-07-02T16:35:06.249Z","phase":"Phase 2","brief_title":"Response to PARP Inhibitor Predicted by the RAD51 Assay","source_id_and_acronym":"NCT03044795 - REPAIR","lead_sponsor":"University Medical Center Groningen","biomarkers":" ER • BRCA1 • BRCA2 • BRCA • MUC16 • RAD51 • IL2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["ER • BRCA1 • BRCA2 • BRCA • MUC16 • RAD51 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2024-05-03"},{"id":"f976983e-6e5c-40aa-ba00-71e22eb80e0e","acronym":"ATRIUM","url":"https://clinicaltrials.gov/study/NCT05338346","created_at":"2022-04-21T15:55:20.706Z","updated_at":"2024-07-02T16:35:08.451Z","phase":"Phase 1","brief_title":"A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies","source_id_and_acronym":"NCT05338346 - ATRIUM","lead_sponsor":"Antengene Discovery Limited","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" TP53 mutation • FANCF mutation","tags":["BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FANCF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATG-018"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-22"},{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"e9a0c2de-92c2-4b8a-8b7f-5e473ce5f549","acronym":"ARIANES","url":"https://clinicaltrials.gov/study/NCT04276376","created_at":"2023-01-23T18:00:08.144Z","updated_at":"2024-07-02T16:35:12.843Z","phase":"Phase 2","brief_title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","source_id_and_acronym":"NCT04276376 - ARIANES","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rubraca (rucaparib)"],"overall_status":"Suspended","enrollment":" Enrollment 130","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-26"},{"id":"74fab00e-e59b-494f-917f-dc80d3cf68bd","acronym":"NCI-2015-01779","url":"https://clinicaltrials.gov/study/NCT02589522","created_at":"2024-03-25T19:35:37.933Z","updated_at":"2024-07-02T16:35:12.957Z","phase":"Phase 1","brief_title":"Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors","source_id_and_acronym":"NCT02589522 - NCI-2015-01779","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 08/23/2021","primary_completion_date":" 08/23/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"1bada8c3-f2f1-4030-ad23-c27e1828e629","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550494","created_at":"2021-01-18T21:45:36.970Z","updated_at":"2024-07-02T16:35:16.133Z","phase":"Phase 2","brief_title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","source_id_and_acronym":"NCT04550494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation","tags":["BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/26/2021","start_date":" 04/26/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"}]